A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)
This study is testing a new medication called TYRA-200 for adults with advanced bile duct cancer and other solid tumors that have specific gene changes. Researchers want to see how safe the medicine is, what the best dose is, and if it can help shrink tumors.
Adults aged 18 and older with advanced solid tumors or bile duct cancer involving specific FGFR2 gene changes may qualify. Standard treatments must have previously failed, stopped working, or been refused by the patient.
Participants will take the study drug TYRA-200 by mouth once a day in repeating 28-day cycles. Doctors will closely monitor participants to check for side effects and see how the tumor responds to treatment.
The study takes place at medical centers in cities such as San Francisco, Boston, and Columbus. This study is currently active but is not looking for new participants at this time.
- 1Testing a new targeted medicine called TYRA-200
- 2For adults with advanced tumors and specific gene changes
- 3Currently active but not enrolling new participants
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.